Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lung Diseases × Gemcitabine × Clear all

Phase

Phase 3 2 Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Extranodal NK-T-Cell 2 Thoracic Neoplasms 1 Squamous Non-small-cell Lung Cancer 1 Oligospermia 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Lung Diseases 1 Fibrosis 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Adenocarcinoma Pancreas 1 Adenocarcinoma 1

Interventions

Carboplatin 2 Vinorelbine 1 Pemetrexed 1 Paclitaxel 1 One-Lung Ventilation 1 Nivolumab 1 Natriuretic Peptide, Brain 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 Anesthesia, General 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡